GSK Moves Up US Filing Timeline For Triple Respiratory Combo
This article was originally published in The Pink Sheet Daily
The company expects to file a once-daily, closed triple combination containing a corticosteroid, a LABA and LAMA by the end of 2016, rather than the first half of 2018, as previously forecast.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.